Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM
Heres why: GLP-1 mimics a hormone that controls appetite and slows digestion
Not everyone faces the same cancer risk, and personal circumstances should guide the approach to any substance with theoretical oncological concerns
Given that GLP-1 therapy builds gradually, each weeks delay can blunt patient enthusiasm and worsen clinical inertia
"A lot more needs to be done to regulate this space,"Dr Yip said
Whether you are a researcher exploring new territory, a patient frustrated by partial relief, or a clinician curious about what your colleagues are seeing, every section that follows is built on what the science actually says right now, not what we hope it will say later